236 related articles for article (PubMed ID: 27779106)
21. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
22. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
Govindan SV; Cardillo TM; Moon SJ; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2009 Oct; 15(19):6052-61. PubMed ID: 19789330
[TBL] [Abstract][Full Text] [Related]
23. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
24. Mutant KRAS is a druggable target for pancreatic cancer.
Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
[TBL] [Abstract][Full Text] [Related]
25. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
26. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
27. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan.
Rodriguez Lanzi C; Wei R; Luo D; Mackenzie GG
Neoplasia; 2022 Feb; 24(2):133-144. PubMed ID: 34968866
[TBL] [Abstract][Full Text] [Related]
28. A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.
Ganaie AA; Siddique HR; Sheikh IA; Parray A; Wang L; Panyam J; Villalta PW; Deng Y; Konety BR; Saleem M
Mol Carcinog; 2020 Aug; 59(8):886-896. PubMed ID: 32291806
[TBL] [Abstract][Full Text] [Related]
29. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
30. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
31. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
32. Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2.
Sakai S; Iwata C; Tanaka HY; Cabral H; Morishita Y; Miyazono K; Kano MR
J Control Release; 2016 May; 230():109-15. PubMed ID: 27080571
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
[TBL] [Abstract][Full Text] [Related]
34. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
[TBL] [Abstract][Full Text] [Related]
35. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.
Fox RG; Lytle NK; Jaquish DV; Park FD; Ito T; Bajaj J; Koechlein CS; Zimdahl B; Yano M; Kopp J; Kritzik M; Sicklick J; Sander M; Grandgenett PM; Hollingsworth MA; Shibata S; Pizzo D; Valasek M; Sasik R; Scadeng M; Okano H; Kim Y; MacLeod AR; Lowy AM; Reya T
Nature; 2016 Jun; 534(7607):407-411. PubMed ID: 27281208
[TBL] [Abstract][Full Text] [Related]
36. Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening.
Pérez-Torras S; Vidal-Pla A; Miquel R; Almendro V; Fernández-Cruz L; Navarro S; Maurel J; Carbó N; Gascón P; Mazo A
Cell Oncol (Dordr); 2011 Dec; 34(6):511-21. PubMed ID: 21681527
[TBL] [Abstract][Full Text] [Related]
37. Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.
London CA; Acquaviva J; Smith DL; Sequeira M; Ogawa LS; Gardner HL; Bernabe LF; Bear MD; Bechtel SA; Proia DA
Clin Cancer Res; 2018 Dec; 24(24):6396-6407. PubMed ID: 30171047
[TBL] [Abstract][Full Text] [Related]
38. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
39. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216.
Mohelnikova-Duchonova B; Kocik M; Duchonova B; Brynychova V; Oliverius M; Hlavsa J; Honsova E; Mazanec J; Kala Z; Ojima I; Hughes DJ; Doherty JE; Murray HA; Crockard MA; Lemstrova R; Soucek P
Pharmacogenomics J; 2017 Oct; 17(5):452-460. PubMed ID: 27573236
[TBL] [Abstract][Full Text] [Related]
40. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
